Stock Analysis of Altimmune Inc (ALT) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code ALT
Close 7.22
Change -0.500 / 6.48 %
Volume 3044.83 K
Vol Change -1506.08 K / 33.09 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthNeutral
Growth Index Poor Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index Low Stability Stock


Fundamental View of Altimmune Inc
PE (TTM)

-1097.81

Very Poor
Price / Book

561.11

Very Poor
Price / Sales

227928

Very Poor
Piotroski F Score

3.0

Not Good
Market Cap

511864 K

Enterprise Value

377202 K

ROA (TTM)

-46.33

Very Poor
ROE (TTM)

-51.11

Very Poor
Net Margin (TTM)

-20762.21

Very Poor
Revenue

510.29 %

279000
Net Profit

7.37 %

-78466.00 K
Debt to Equity

0.0026

Excellent
Altman Z Score

15.33

Excellent
Quick Ratio

0

Poor
Cash Ratio

16.29

Excellent


Highs/Lows of Altimmune Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week7.3 1.10 % 1.85 % 8.07516.8109-May-2408-May-24
Two Week7.26 0.551 % 2.41 % 8.07516.28209-May-2429-Apr-24
One Month8.01 9.86 % 1.20 % 8.546.28211-Apr-2429-Apr-24
Three Month10.44 30.84 % 3.90 % 14.846.28228-Feb-2429-Apr-24
Six Months2.5 188.80 % 18.29 % 14.842.31528-Feb-2413-Nov-23
One year4.98 44.98 % 26.22 % 14.842.0928-Feb-2423-Oct-23
Two year4.27 69.09 % 30.53 % 17.172.0913-Jan-2323-Oct-23
Five year2.77 160.65 % 81.25 % 23.491.5102-Sep-2219-Nov-19
Ten year447.0 98.38 % 178.03 % 1050.01.5119-Jan-1719-Nov-19


Technical View of Altimmune Inc
RSI

44.74

Neutral
MACD

-0.336

Bullish
ADX

14.09

Mild Bearish
Super Trend

8.49

Mild Bearish
Williams %R

-51.85

Neutral
CCI

44.30

Strong Bearish


EMA 5

7.32

Neutral
EMA 15

7.34

Whipsaw
EMA 50

8.15

Mild Bearish
EMA 100

8.09

Mild Bearish
SMA 100

9.39

Mild Bearish
SMA 200

6.20

Bullish
SMA 5 / 20

7.35 / 7.19

Strong Bullish
SMA 15 / 50

7.19 / 8.63

Mild Bearish
SMA 50 / 200

8.63 / 6.20

Bullish




Charts of Altimmune Inc


Returns of Altimmune Inc with Peers
Period / StockALTADPTCELCKALV
1 Week-1.10%16.28%-4.75%-0.412%
1 Mth-9.86%31.09%-13.16%1.26%
3 Mth-30.84%-7.41%12.20%-24.50%
6mth188.80%-0.285%56.27%49.69%
1 Year44.98%-50.84%73.86%24.15%
2 Year69.09%-51.59%141.81%8.34%
5 Years160.65%--24.36%-50.97%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Altimmune Inc with Peers
Ratio / StockALTADPTCELCKALV
PE-1097.81-2.36-6.18-2892.78
P/B561.111.447.782277.36
ROA-46.33-30.25-66.54-67.71
ROE-51.11-60.92-80.36-78.73
Debt To Equity0.00260.03040.2660.0068
Revenue279000
510.29 % 		179690 K
3.03 % 		0
% 		0
%
Net Income-78466.00 K
7.37 % 		-195937.00 K
2.12 % 		-56511.99 K
39.98 % 		-92907.00 K
12.83 %


Technicals of Altimmune Inc with Peers
Technical / StockALTADPTCELCKALV-
ADX14.0921.2114.3717.66
CMF-0.103-0.01690.02520.055
MFI52.6285.5447.5456.16
RSI44.7464.4744.8255.25
MACD Abv SignalTrueTrueTrueTrue
Price Above 50 MAFalseTrueFalseTrue-
Price Above 200 MATrueFalseTrueTrue-


About : Altimmune Inc

Address : 910 Clopper Road, Gaithersburg, MD, United States, 20878
Tel : 240 654 1450
URL : https://altimmune.com
Code : ALT, ISIN : US02155H2004, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 06_Oct_2005
Employee Count : 59

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.


Note : All Data Generated at the End of Trading Hours (EOD Data)